tiprankstipranks
Trending News
More News >
Exelixis (EXEL)
:EXEL
US Market

Exelixis (EXEL) Stock Forecast & Price Target

Compare
2,953 Followers
See the Price Targets and Ratings of:

EXEL Analyst Ratings

Moderate Buy
16Ratings
Moderate Buy
10 Buy
6 Hold
0 Sell
Based on 16 analysts giving stock ratings to
Exelixis
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

EXEL Stock 12 Month Forecast

Average Price Target

$41.71
▼(-1.56%Downside)
Based on 16 Wall Street analysts offering 12 month price targets for Exelixis in the last 3 months. The average price target is $41.71 with a high forecast of $56.00 and a low forecast of $29.00. The average price target represents a -1.56% change from the last price of $42.37.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"20":"$20","57":"$57","29.25":"$29.3","38.5":"$38.5","47.75":"$47.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":56,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$56.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":41.71,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$41.71</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":29,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$29.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[20,29.25,38.5,47.75,57],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Dec<br/>2024","9":"Mar<br/>2025","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,42.88,43.88923076923077,44.89846153846154,45.90769230769231,46.91692307692308,47.926153846153845,48.93538461538461,49.94461538461539,50.95384615384616,51.963076923076926,52.972307692307695,53.98153846153846,54.99076923076923,{"y":56,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,42.88,42.79,42.7,42.61,42.52,42.43,42.34,42.25,42.160000000000004,42.07,41.980000000000004,41.89,41.800000000000004,{"y":41.71,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,42.88,41.8123076923077,40.744615384615386,39.67692307692308,38.60923076923077,37.541538461538465,36.473846153846154,35.40615384615385,34.33846153846154,33.27076923076923,32.20307692307692,31.135384615384616,30.067692307692308,{"y":29,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":21.92,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.25,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.22,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.03,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.3,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.12,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.59,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.3,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.15,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.69,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.39,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.89,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":42.88,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$56.00Average Price Target$41.71Lowest Price Target$29.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on EXEL
TipRanks AITipRanks
Not Ranked
TipRanks
$50
Buy
18.01%
Upside
Reiterated
05/27/25
Exelixis receives a strong score driven by excellent financial performance, positive earnings call outcomes, and favorable technical indicators. While the valuation is reasonable, the absence of a dividend yield and operational expense challenges slightly temper the overall outlook. The strategic focus on pipeline development and a robust cash position further bolster confidence in its growth trajectory.
Bank of America Securities Analyst forecast on EXEL
Jason GerberryBank of America Securities
Bank of America Securities
$45$46
Hold
8.57%
Upside
Reiterated
06/05/25
Exelixis's Zanza Pipeline: Balancing Risks and Opportunities Ahead of Key 2025 Readouts
Truist Financial Analyst forecast on EXEL
Asthika GoonewardeneTruist Financial
Truist Financial
Buy
Reiterated
06/05/25
Truist Financial Sticks to Its Buy Rating for Exelixis (EXEL)
Wells Fargo Analyst forecast on EXEL
Derek ArchilaWells Fargo
Wells Fargo
$50$36
Hold
-15.03%
Downside
Reiterated
06/03/25
Exelixis (EXEL) Gets a Hold from Wells Fargo
Stifel Nicolaus Analyst forecast on EXEL
Stephen WilleyStifel Nicolaus
Stifel Nicolaus
$38
Hold
-10.31%
Downside
Reiterated
06/03/25
Stifel Nicolaus Reaffirms Their Hold Rating on Exelixis (EXEL)
Citizens JMP Analyst forecast on EXEL
Silvan TuerkcanCitizens JMP
Citizens JMP
$46$47
Buy
10.93%
Upside
Reiterated
06/03/25
Citizens JMP Sticks to Its Buy Rating for Exelixis (EXEL)
William Blair Analyst forecast on EXEL
Andy HsiehWilliam Blair
William Blair
Buy
Reiterated
06/02/25
Promising Clinical Data and Ongoing Trials Justify Buy Rating for Exelixis's Zanzalintinib
Citi
$56
Buy
32.17%
Upside
Reiterated
05/22/25
Exelixis's Growth Potential Highlighted by Promising STELLAR-002 Trial Results and Buy Rating
Guggenheim Analyst forecast on EXEL
Michael SchmidtGuggenheim
Guggenheim
$42$45
Buy
6.21%
Upside
Reiterated
05/14/25
Exelixis price target raised to $45 from $42 at GuggenheimExelixis price target raised to $45 from $42 at Guggenheim
Lucid Capital Analyst forecast on EXEL
Christopher LiuLucid Capital
Lucid Capital
$36$37
Hold
-12.67%
Downside
Reiterated
05/14/25
Exelixis (EXEL) PT Raised to $37 at Lucid Capital MarketsLucid Capital Markets analyst Christopher Liu raised the price target on Exelixis (NASDAQ: EXEL) to $37.00 (from $36.00) while maintaining a Neutral rating.
Morgan Stanley Analyst forecast on EXEL
Sean LaamanMorgan Stanley
Morgan Stanley
$40$47
Buy
10.93%
Upside
Reiterated
05/14/25
Exelixis: Strong Financial Performance and Promising Pipeline Drive Buy Rating
Leerink Partners Analyst forecast on EXEL
Andrew BerensLeerink Partners
Leerink Partners
$33$37
Hold
-12.67%
Downside
Reiterated
05/14/25
Exelixis: Hold Rating Amid Strong Revenue and Uncertain Prospects
Barclays Analyst forecast on EXEL
Peter LawsonBarclays
Barclays
$29
Hold
-31.56%
Downside
Reiterated
05/14/25
Exelixis (EXEL) Gets a Hold from Barclays
RBC Capital Analyst forecast on EXEL
Gregory RenzaRBC Capital
RBC Capital
$40
Buy
-5.59%
Downside
Reiterated
05/13/25
RBC Capital Sticks to Their Buy Rating for Exelixis (EXEL)
TD Cowen Analyst forecast on EXEL
Yaron WerberTD Cowen
TD Cowen
$44
Buy
3.85%
Upside
Reiterated
05/13/25
Exelixis's Strong Financial Performance and Promising Pipeline Drive Optimistic Outlook and Increased Price Target
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on EXEL
TipRanks AITipRanks
Not Ranked
TipRanks
$50
Buy
18.01%
Upside
Reiterated
05/27/25
Exelixis receives a strong score driven by excellent financial performance, positive earnings call outcomes, and favorable technical indicators. While the valuation is reasonable, the absence of a dividend yield and operational expense challenges slightly temper the overall outlook. The strategic focus on pipeline development and a robust cash position further bolster confidence in its growth trajectory.
Bank of America Securities Analyst forecast on EXEL
Jason GerberryBank of America Securities
Bank of America Securities
$45$46
Hold
8.57%
Upside
Reiterated
06/05/25
Exelixis's Zanza Pipeline: Balancing Risks and Opportunities Ahead of Key 2025 Readouts
Truist Financial Analyst forecast on EXEL
Asthika GoonewardeneTruist Financial
Truist Financial
Buy
Reiterated
06/05/25
Truist Financial Sticks to Its Buy Rating for Exelixis (EXEL)
Wells Fargo Analyst forecast on EXEL
Derek ArchilaWells Fargo
Wells Fargo
$50$36
Hold
-15.03%
Downside
Reiterated
06/03/25
Exelixis (EXEL) Gets a Hold from Wells Fargo
Stifel Nicolaus Analyst forecast on EXEL
Stephen WilleyStifel Nicolaus
Stifel Nicolaus
$38
Hold
-10.31%
Downside
Reiterated
06/03/25
Stifel Nicolaus Reaffirms Their Hold Rating on Exelixis (EXEL)
Citizens JMP Analyst forecast on EXEL
Silvan TuerkcanCitizens JMP
Citizens JMP
$46$47
Buy
10.93%
Upside
Reiterated
06/03/25
Citizens JMP Sticks to Its Buy Rating for Exelixis (EXEL)
William Blair Analyst forecast on EXEL
Andy HsiehWilliam Blair
William Blair
Buy
Reiterated
06/02/25
Promising Clinical Data and Ongoing Trials Justify Buy Rating for Exelixis's Zanzalintinib
Citi
$56
Buy
32.17%
Upside
Reiterated
05/22/25
Exelixis's Growth Potential Highlighted by Promising STELLAR-002 Trial Results and Buy Rating
Guggenheim Analyst forecast on EXEL
Michael SchmidtGuggenheim
Guggenheim
$42$45
Buy
6.21%
Upside
Reiterated
05/14/25
Exelixis price target raised to $45 from $42 at GuggenheimExelixis price target raised to $45 from $42 at Guggenheim
Lucid Capital Analyst forecast on EXEL
Christopher LiuLucid Capital
Lucid Capital
$36$37
Hold
-12.67%
Downside
Reiterated
05/14/25
Exelixis (EXEL) PT Raised to $37 at Lucid Capital MarketsLucid Capital Markets analyst Christopher Liu raised the price target on Exelixis (NASDAQ: EXEL) to $37.00 (from $36.00) while maintaining a Neutral rating.
Morgan Stanley Analyst forecast on EXEL
Sean LaamanMorgan Stanley
Morgan Stanley
$40$47
Buy
10.93%
Upside
Reiterated
05/14/25
Exelixis: Strong Financial Performance and Promising Pipeline Drive Buy Rating
Leerink Partners Analyst forecast on EXEL
Andrew BerensLeerink Partners
Leerink Partners
$33$37
Hold
-12.67%
Downside
Reiterated
05/14/25
Exelixis: Hold Rating Amid Strong Revenue and Uncertain Prospects
Barclays Analyst forecast on EXEL
Peter LawsonBarclays
Barclays
$29
Hold
-31.56%
Downside
Reiterated
05/14/25
Exelixis (EXEL) Gets a Hold from Barclays
RBC Capital Analyst forecast on EXEL
Gregory RenzaRBC Capital
RBC Capital
$40
Buy
-5.59%
Downside
Reiterated
05/13/25
RBC Capital Sticks to Their Buy Rating for Exelixis (EXEL)
TD Cowen Analyst forecast on EXEL
Yaron WerberTD Cowen
TD Cowen
$44
Buy
3.85%
Upside
Reiterated
05/13/25
Exelixis's Strong Financial Performance and Promising Pipeline Drive Optimistic Outlook and Increased Price Target
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Exelixis

1 Month
xxx
Success Rate
17/27 ratings generated profit
63%
Average Return
+8.07%
reiterated a xxx
rating 24 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 62.96% of your transactions generating a profit, with an average return of +8.07% per trade.
3 Months
xxx
Success Rate
23/27 ratings generated profit
85%
Average Return
+25.26%
reiterated a xxx
rating 24 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 85.19% of your transactions generating a profit, with an average return of +25.26% per trade.
1 Year
Gregory RenzaRBC Capital
Success Rate
24/27 ratings generated profit
89%
Average Return
+28.99%
reiterated a buy rating 25 days ago
Copying Gregory Renza's trades and holding each position for 1 Year would result in 88.89% of your transactions generating a profit, with an average return of +28.99% per trade.
2 Years
xxx
Success Rate
27/27 ratings generated profit
100%
Average Return
+62.13%
reiterated a xxx
rating 25 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +62.13% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

EXEL Analyst Recommendation Trends

Rating
Feb 25
Mar 25
Apr 25
May 25
Jun 25
Strong Buy
0
0
0
0
0
Buy
28
34
22
23
19
Hold
21
22
12
11
11
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
49
56
34
34
30
In the current month, EXEL has received 19 Buy Ratings, 11 Hold Ratings, and 0 Sell Ratings. EXEL average Analyst price target in the past 3 months is 41.71.
Each month's total comprises the sum of three months' worth of ratings.

EXEL Financial Forecast

EXEL Earnings Forecast

Next quarter’s earnings estimate for EXEL is $0.64 with a range of $0.59 to $0.68. The previous quarter’s EPS was $0.62. EXEL beat its EPS estimate 100.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.04% of the time in the same period. In the last calendar year EXEL has Outperformed its overall industry.
Next quarter’s earnings estimate for EXEL is $0.64 with a range of $0.59 to $0.68. The previous quarter’s EPS was $0.62. EXEL beat its EPS estimate 100.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.04% of the time in the same period. In the last calendar year EXEL has Outperformed its overall industry.

EXEL Sales Forecast

Next quarter’s sales forecast for EXEL is $574.36M with a range of $549.00M to $599.00M. The previous quarter’s sales results were $555.45M. EXEL beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 47.49% of the time in the same period. In the last calendar year EXEL has Outperformed its overall industry.
Next quarter’s sales forecast for EXEL is $574.36M with a range of $549.00M to $599.00M. The previous quarter’s sales results were $555.45M. EXEL beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 47.49% of the time in the same period. In the last calendar year EXEL has Outperformed its overall industry.

EXEL Stock Forecast FAQ

What is EXEL’s average 12-month price target, according to analysts?
Based on analyst ratings, Exelixis’s 12-month average price target is 41.71.
    What is EXEL’s upside potential, based on the analysts’ average price target?
    Currently there's no upside potential for EXEL, based on the analysts’ average price target.
    Can I see which stocks the top-ranking analysts are rating?
    Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
      How can I follow the stock ratings of top Wall Street analysts?
      Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
        Is EXEL a Buy, Sell or Hold?
        Exelixis has a consensus rating of Moderate Buy which is based on 10 buy ratings, 6 hold ratings and 0 sell ratings.
          What is Exelixis’s price target?
          The average price target for Exelixis is 41.71. This is based on 16 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
          The highest analyst price target is $56.00 ,the lowest forecast is $29.00. The average price target represents -1.56% Decrease from the current price of $42.37.
            What do analysts say about Exelixis?
            Exelixis’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 16 Wall Streets Analysts.
              How can I buy shares of EXEL?
              Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                What am I Missing?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis